Drug sampling in many places failed!

Medicines are special commodities and are closely related to human health and safety
.
Therefore, in order to ensure the safety of people's medicines, the supervision of pharmaceutical companies has been continuously increased by the state and various regions
.
Since the beginning of this year, many places have successively released a series of sampling results, among which a large number of pharmaceutical companies have been ordered to rectify and fined
.
For example, recently, the Hubei Provincial Food and Drug Administration issued the first phase of the drug quality announcement in 2022
.
According to the announcement, there were 26 batches of drugs and 2 batches of pharmaceutical packaging materials were unqualified in the random inspection, namely Digupi, Suanzaoren, Jincao, Helian, Liyan Syrup, Scutellaria baicalensis (tablets), Saponin thorn, Patchouli Fragrant, Jianwei Xiaoshi Tablets, White Fresh Skin, Naoxinshu Oral Liquid, Vinegar Yanhu, Suoganteng, Medicinal Low Density Polyethylene Bags, Dianjixueteng, Honeysuckle,
etc.
It is understood that two of the unqualified pharmaceutical companies have cancelled the "Drug Production License", namely Hubei Jurui Traditional Chinese Medicine Co.
, Ltd.
and Bozhou Huayun Traditional Chinese Medicine Co.
,
Ltd.
Both companies have been fined many times for repeatedly producing inferior drugs
.
At present, the Hubei Provincial Drug Administration has instructed relevant departments to take necessary control measures such as sealing up, detaining, suspending sales, and recalling drugs that do not meet the requirements, and investigate and punish the production enterprises and sampled units in accordance with relevant laws and regulations
.
On April 6, the Fujian Provincial Food and Drug Administration also issued a notice on the results of the first phase of drug quality random inspection in 2022
.
The carding found that 4 batches of drugs from 4 drug manufacturers were found to be unqualified this time
.
The unqualified drugs included three pieces of Chinese herbal medicines: Schisandra chinensis, Haijinsha, and rose; and one western medicine: oxytetracycline tablets
.
Unqualified items include content determination, total ash, characters, and weight differences
.
For the above-mentioned products and enterprises that fail to pass the random inspection, the Fujian Provincial Food and Drug Administration has organized inspections and disposals in accordance with the law, and has also filed a case for investigation and punishment of suspected illegal enterprises
.
On March 3, the Jiangxi Provincial Food and Drug Administration issued an announcement on the second phase of drug supervision and sampling inspection in Jiangxi Province in 2022.

.
The announcement shows that a total of 12 batches of drugs from 12 drug manufacturers did not meet the regulations in this sampling inspection.
Among them, Chinese herbal decoction pieces are still "famous on the list", involving many varieties of Chinese medicine decoction pieces such as vinegar turtle, Acanthopanax senticosus, and vinegar Corydalis
.
From the point of view of unqualified items, it is mainly for the impurities of drug scraps, content determination, aflatoxin and so on
.
Regarding the drugs that do not meet the regulations, the Jiangxi Provincial Food and Drug Administration stated that it has instructed the relevant departments to take necessary control measures such as sealing, detaining, suspending sales, and recalling the drugs that do not meet the regulations, and sampling manufacturers and samples in accordance with relevant laws and regulations.
unit to investigate
.
On the whole, the unqualified drugs are mostly Chinese herbal medicines, decoction pieces and oral solid preparations
.
Among them, unqualified Chinese herbal medicines and decoction pieces still account for the majority
.
In this regard, the industry believes that in the context of increasingly strict supervision of the Chinese herbal medicine industry, relevant pharmaceutical companies need to further strengthen self-discipline, and strictly follow the requirements of the new version of the Pharmacopoeia, and do a good job in planting, production, processing, circulation and other links.
work to boost the overall quality of the decoction piece industry
.
It should be noted that, in fact, frequent sampling means that the safety of drugs has become the focus of attention in the industry
.
In order to strengthen drug quality supervision and ensure the safety of public medication, relevant departments will continue to strengthen drug quality supervision and sampling
.
In this context, all pharmaceutical companies need to strictly abide by regulations and control the quality of production in all aspects; at the same time, they must continue to innovate and improve the system to enhance product competitiveness and continue to improve their ability to manage the challenges of drug safety risks and risks.
level, and boost the development of the entire pharmaceutical industry in the direction of higher quality
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.